Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352141 | 0.94 | LMNA (0.41) | ALDH1A1LMNAKDM4EAKR1B10AKR1B1 | |
| SCHEMBL16352110 | 0.92 | FFAR1 (0.39) | LMNAL3MBTL1ALOX5 | |
| SCHEMBL16352146 | 0.88 | MET (0.37) | ALDH1A1LMNAKDM4EAKR1B10AKR1B1 | |
| SCHEMBL16352148 | 0.88 | LTB4R (0.38) | ALDH1A1LTB4RLTB4R2LMNAKDM4E | |
| SCHEMBL16352111 | 0.86 | L3MBTL1 (0.45) | ALDH1A1L3MBTL1ALOX5 | |
| SCHEMBL16352109 | 0.86 | ALOX5 (0.42) | ALDH1A1ALOX5 | |
| SCHEMBL16352145 | 0.80 | L3MBTL1 (0.40) | LMNAL3MBTL1GAAALOX5 | |
| SCHEMBL16352147 | 0.79 | NR4A2 (0.40) | L3MBTL1AKR1B1 | |
| SCHEMBL16363706 | 0.79 | S1PR2 (0.44) | LMNAKDM4E | |
| SCHEMBL16352096 | 0.79 | FDPS (0.40) | HCAR2ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593136-B2 | Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase | THE GEORGE WASHINGTON UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | DCXR, G6PD, GRHPR | HCAR2 2800/4885ALDH1A1 589/4885LTB4R 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.